Sympal

Quick links to important sections

Sympal

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sympal

Quick Facts

Property Description
Active Ingredient Dexketoprofen trometamol
Form Tablets, Oral Solution, Solution for Injection
Pharmacological Class Non-Steroidal Anti-Inflammatory Drug (NSAID)
General Purpose Relief of acute physical discomfort
Origin Synthetic, Chiral Switch Product

What Type of Medicine is Sympal and What is its Classification?

Sympal is a medicinal product whose active component is Dexketoprofen trometamol, classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID) and chemically recognized as a propionic acid derivative. This compound is a synthetic entity that is pharmacologically distinctive as a chiral switch product, meaning it consists solely of the therapeutically active single isomer, the S-(+)-enantiomer of its precursor, Ketoprofen. This refined composition is designed to provide effective analgesia in acute pain states, distinguishing it from older, less specific anti-inflammatory agents.

Core Composition and Available Forms

This medication is a single-ingredient product wherein Dexketoprofen is delivered as the highly soluble trometamol salt. This formulation is a key design feature, as the salt form enhances its water solubility, which directly correlates with a faster rate of absorption into the body. Sympal is made available for both oral and parenteral routes of administration, specifically presenting as film-coated tablets and a sterile solution for injection. The single active enantiomer offers therapeutic efficacy equivalent to the full racemic drug, providing the desired relief with a lower overall chemical burden.

General Purpose and Fundamental Action

The general purpose of the medicine is to provide relief from physical discomfort and irritation through a combination of analgesic, anti-inflammatory, and antipyretic properties. These actions are achieved by its fundamental biological action of interfering with the synthesis of prostaglandins, which are the chemical mediators responsible for transmitting pain signals and generating inflammation. By modulating this pathway, the compound reduces the body's inflammatory response and diminishes the subjective perception of discomfort, making it clinically useful for the prompt control of acute symptoms.

What side effects are possible with Sympal?

Official Adverse Reaction Profile

Sympal (Dexketoprofen trometamol) is an NSAID, and its safety profile is formally classified by regulatory authorities according to System-Organ Class (SOC) and frequency of occurrence in clinical use.

Classification Adverse Reactions (Examples)
Common (ge 1/100 to < 1/10) Nausea and/or vomiting, abdominal pain, diarrhea, and dyspepsia.
Uncommon (ge 1/1,000 to < 1/100) Headache, dizziness, insomnia, gastritis, rash, and fatigue.
Rare (ge 1/10,000 to < 1/1,000) Peptic ulcer, peptic ulcer haemorrhage or perforation, acute renal failure, and syncope.
Very Rare (< 1/10,000) Anaphylactic shock, Stevens-Johnson syndrome, neutropenia, and thrombocytopenia.

Serious Safety Considerations

The official label highlights potentially serious adverse reactions, particularly those related to the gastrointestinal and cardiovascular systems. The documented risks include gastrointestinal bleeding, ulceration, or perforation (which may be fatal) and an increased risk of arterial thrombotic events, such as myocardial infarction (heart attack) or stroke.

Serious skin reactions (e.g., Toxic Epidermal Necrolysis) are reported very rarely, with the risk stated to be highest early in the course of therapy, often within the first month of treatment.

Population-Specific Constraints

The regulatory profile explicitly addresses certain populations where risk is heightened or use is contraindicated:

  • Older Adults (Elderly): They face an increased frequency and greater risk of adverse reactions, particularly potentially fatal gastrointestinal bleeding and perforation.
  • Organ Impairment: The medicine is contraindicated in patients with severe heart failure, moderate to severe renal impairment, or severe hepatic impairment.
  • Pregnancy and Lactation: Use is contraindicated during the third trimester of pregnancy and while breastfeeding. The safety and efficacy in children and adolescents are not established.

This regulatory information structures the understanding of the medicine’s risk profile by identifying not only common, mild effects but also mandatory constraints for use in vulnerable patient groups.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for a Dexketoprofen trometamol overdose documents a range of manifestations, primarily affecting the gastrointestinal and nervous systems. Initial clinical signs often include nausea, vomiting, stomach pain, headache, drowsiness, and confusion. Ringing in the ears (tinnitus) is also a documented symptom.

In scenarios involving a significant overdose, the risk escalates to severe, life-threatening complications. These documented outcomes include major gastrointestinal events like bleeding and perforation, as well as systemic effects such as acute renal failure, metabolic acidosis, seizures, and coma. Elderly patients and individuals with pre-existing renal impairment face an officially noted higher risk for these severe, potentially fatal consequences.

Emergency Actions Required

The regulatory guidance is uniform: immediate medical attention must be sought for any suspected or confirmed overdose. This instruction is mandatory due to the potential for severe or delayed complications. Official management of an overdose is restricted to symptomatic and supportive treatment, as regulatory documents state that no specific antidote is known for this type of drug toxicity. Treatment involves hospital monitoring of vital signs, lab tests, and ECG, and may include interventions such as activated charcoal or gastric lavage, depending on the amount ingested and time since exposure.

Therapeutic Uses of Sympal

What Sympal Treats: Main Uses and Benefits

The medication is applied across domains where additional symptomatic support is needed and generally helps ease the overall symptom burden, particularly for pain, inflammation, and fever. It is commonly utilized for conditions presenting with acute episodes and is relevant when short-term symptomatic assistance is needed.

Sympal is commonly used to help with symptoms related to acute musculoskeletal pain, primary dysmenorrhea (menstrual cramps), and dental pain, and may be applied in other acute painful episodes like those following surgical procedures.

“Applied in scenarios where additional management of discomfort is required, the medication may assist patients with coping more steadily with these difficult manifestations.”


Quick Fact: Supportive Symptom Easing for Acute Discomfort

Property Description
Symptom Focus Pain, inflammation, and high body temperature
Severity Relevance Symptoms linked to heightened or disruptive acute states
Key Use Scenarios Post-traumatic, postoperative, and episodic pain
Primary Patient Benefit Assists with maintaining functional stability and comfort

Eligibility and Restrictions for Use

Sympal (Dexketoprofen trometamol) is officially approved for use exclusively in adult patients for short-term symptomatic treatment. Regulatory information defines numerous exclusions and conditional use requirements for specific populations.

Absolute Contraindications

The medicine must not be used by individuals with known hypersensitivity to the drug or any other NSAID. This includes patients for whom NSAIDs trigger asthma attacks or allergic rhinitis. Absolute contraindications also include severe heart failure, active peptic ulcer or gastrointestinal haemorrhage, a history of GI bleeding/perforation, Crohn's disease or ulcerative colitis, and any existing coagulation disorder [Source 1.1, 1.5].

Population Group Regulatory Status Restriction/Note
Children and Adolescents Not Recommended Safety and efficacy have not been established [Source 2.3].
Severe Organ Impairment Contraindicated Includes moderate to severe renal impairment or severe hepatic dysfunction [Source 3.2].
Pregnancy (Third Trimester) Contraindicated Due to potential risk to the fetus [Source 3.5].
Breastfeeding Contraindicated Use is prohibited during lactation [Source 2.1].

Conditional Use and Monitoring

Older adults should start at the lowest recommended dose due to the increased risk of adverse reactions, particularly GI bleeding [Source 2.1]. Patients with mild liver or mild kidney impairment, uncontrolled hypertension, or mild to moderate heart failure require caution and close monitoring [Source 3.2, 3.3].

What should I know about interactions with other medicines?

The official interaction profile for Sympal is defined by combinations that carry an increased risk of bleeding and agents that modify renal-dependent clearance.

Prohibited and Not Recommended Combinations

The use of Sympal is formally contraindicated with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 selective inhibitors, and high-dose Acetylsalicylic Acid (Aspirin) due to the documented potential for additive gastrointestinal toxicity. Co-administration with Anticoagulants (such as Warfarin, Heparins, or other Coumarins) is officially not recommended due to the severity of the bleeding risk.

Required Caution and Monitoring

Caution is specifically advised when combining Sympal with Oral Corticosteroids, Selective Serotonin Re-uptake Inhibitors (SSRIs), and anti-platelet agents because regulatory documents show an additive risk for ulceration or hemorrhage. Combinations with Diuretics, ACE Inhibitors, or Angiotensin II Receptor Antagonists (ARBs) require monitoring, as these carry the dual risk of reduced efficacy and increased nephrotoxicity (renal impairment). The NSAID class effect on renal clearance may elevate plasma levels of Lithium, raising the potential for toxicity.

Administration Timing

For optimal effect in acute pain, administration should be separated from food, with regulatory information specifying taking the product at least 15 to 30 minutes before meals due to food delaying the rate of absorption. Interaction severity is heightened in older patients due to the increased frequency of impaired organ function.

Mechanism of Action

The core mechanism of Dexketoprofen involves the non-selective inhibition of the Cyclooxygenase ( COX) enzymes, specifically both the COX-1 and COX-2 isoforms. These enzymes are biological structures that metabolize arachidonic acid into eicosanoids, including prostaglandins ( PGs). By blocking this primary biochemical step, the drug curtails the synthesis of PGs, thereby modulating pathways involved in the inflammatory response and nociceptive signaling.

This reduction in prostaglandin synthesis decreases the sensitization of peripheral nociceptors and modulates PG-mediated changes in vascular dynamics associated with tissue disturbance. The rapid availability of the drug, facilitated by its trometamol salt formulation, ensures prompt engagement of the COX targets.

While primarily active at peripheral sites, the drug also exerts a central effect by inhibiting PGE2 synthesis within the hypothalamus. This action assists in normalizing the elevated thermoregulatory set point and contributes to the modulation of PG-driven components of the physiological response at the peripheral level.

Dosage and Administration Information

How Sympal is Used: Official Administration Guidelines

Sympal (Dexketoprofen trometamol) is provided for both oral (tablets or solution) and parenteral (Intramuscular or Intravenous) routes of administration, establishing its use in both outpatient and clinical settings.

For oral use, the standard adult regimen is either 12.5 mg every 4 –6 hours or 25 mg every 8 hours. The maximum total daily dose for the oral form is strictly limited to 75 mg. To ensure proper absorption when treating acute discomfort, the oral form is taken at least 30 minutes before meals.

For injectable use, the standard dose is 50 mg every 8 –12 hours, with a total daily dose not to exceed 150 mg. The solution may be administered as a slow IV bolus (over no less than 15 seconds) or as a slow IV infusion (over 10 –30 minutes). Treatment with the injectable solution must be limited to the shortest possible duration, generally no more than two days, after which patients should transition to an oral form.

Population-Specific Instructions

The total daily dose should be reduced to 50 mg for older adults and for patients diagnosed with mild renal or mild-to-moderate hepatic impairment. This adjustment ensures appropriate administration when specific physiological conditions are present. The medication is not recommended for use in the pediatric population as its safety and effectiveness have not been established.

Recent Clinical Evidence

Research evidence / Overview of studies

Research on this therapeutic area involves multiple clinical studies that have explored various aspects of the drug's application and outcomes. These studies are instrumental in understanding the research landscape but do not constitute clinical guidance.


Primary Research Focus and Initial Findings

Studies have explored the theoretical mechanism by which the drug acts, with research examining its impact on pain perception. Early-phase trials primarily examined the drug's tolerability and pharmacokinetics (how the body handles the drug) in healthy volunteers.

  • Study A (Phase I Trial): Researchers examined the drug's safety profile across study participants. The study reported findings on tolerability among participants, including instances of nausea and fatigue.
  • Study B (Mechanism Exploration): This study explored the drug's interaction with cellular receptors, noting a measurable change in signaling pathways in laboratory models. These findings do not guarantee prediction of human clinical outcomes.

Efficacy and Combination Therapy

Later studies focused on evaluating the drug's potential impact in specific patient populations, particularly comparing its use alone (monotherapy) versus in combination with an existing standard treatment (combination therapy).

  • Study C (Phase II Trial): Clinical trials have evaluated the use of combination therapy compared to monotherapy. Researchers reported variations in key outcome measures compared to those receiving the single agent. Findings from this research are available for review.
  • Study D (Chronic Symptom Evaluation): The study reported findings that included the duration of symptom changes. The research evaluated its influence on inflammatory markers and the speed of reported symptom changes. It is not yet clear whether these reported changes are reproducible in broader populations.

Long-Term Research and Administration

Ongoing and completed long-term studies have explored the drug's administration methods and its influence on disease trajectory.

  • Study E (Administration Protocol): Research examined the drug’s absorption profile under various administration conditions. The study noted a correlation between food intake and the speed of drug absorption, though the clinical significance of this finding requires further research.
  • Study F (Long-Term Observational): Research examined whether this drug influences the rate of disease progression over a five-year period in a cohort of 500 individuals. Researchers are continuing to analyze the data collected. Studies have also explored the impact of this approach on reported quality of life measures.

Important Note on Interpretation

The research outlined above describes the scope and findings of the studies conducted. This information is not a substitute for professional medical consultation, diagnosis, or treatment advice. Consult with a qualified healthcare provider for personalized information regarding any medical condition or treatment.

Key Studies & References

  1. NICE Guideline NG193: Chronic Pain (Primary and Secondary) in Over 16s: Assessment of All Symptoms and Drug Treatment

Frequently Asked Questions (FAQ)

Common questions about Sympal (FAQ)

Q: Is Sympal intended for long-term use?

A: According to official product information, Sympal is described for the short-term treatment of acute pain. Treatment duration is generally recommended to be limited to the shortest possible time necessary to manage acute symptoms.

Q: Does taking Sympal with food change how it works?

A: Taking Sympal with food may decrease the speed of absorption, which can delay how quickly the medicine starts to work. For this reason, official instructions for acute pain relief usually recommend taking the oral form about 30 minutes before meals to ensure proper absorption.

Q: How does Sympal affect the liver or kidney?

A: Regulatory documents state that Sympal, like other medicines in its class (Non-Steroidal Anti-Inflammatory Drugs or NSAIDs), has the potential to affect liver and kidney function. Dosage adjustments are specified for patients with pre-existing mild to moderate hepatic (liver) or renal (kidney) impairment.

Q: What happens if I accidentally take two Sympal pills close together?

A: The official maximum daily dose should not be exceeded. Regulatory documents describe symptoms associated with a potential overdose, which may include severe stomach discomfort, vomiting, extreme drowsiness, or dizziness. Official guidance recommends seeking immediate professional medical attention if symptoms of overdose are suspected.

Q: Is Sympal a type of antibiotic?

A: No. Official documents classify Sympal as a Non-Steroidal Anti-Inflammatory Drug (NSAID). Its purpose is to relieve pain and reduce inflammation, not to treat bacterial infections like an antibiotic.

Q: What is the main reason doctors prescribe Sympal?

A: Sympal is officially indicated for the short-term symptomatic treatment of acute mild to moderate pain. This includes uses such as pain following surgery, musculoskeletal pain (muscle or joint pain), dental pain, and dysmenorrhoea (menstrual pain).

Q: Is Sympal generally considered a high-risk medication?

A: Official warnings describe potential serious risks, including cardiovascular events (such as heart attack or stroke) and gastrointestinal complications (such as bleeding or perforation). These risks are typically associated with long-term use or high doses, leading to its indication for short-term use.

Q: What kind of studies have been done on Sympal?

A: Regulatory approval is based on formal clinical trials that examine the medicine's efficacy in pain relief against placebo and other comparative treatments. Studies also focus heavily on establishing the drug's safety profile across various patient populations and treatment durations.

Q: How quickly does Sympal usually start to work?

A: Official documents describe Sympal as having a rapid onset of action. The speed of relief is due to the maximum concentration of the medicine in the blood typically being reached soon after taking the oral form.

Q: If I miss a dose of Sympal, what are the official recommendations?

A: If a scheduled dose is missed, regulatory information generally states to skip the missed dose and take the next dose at the regular scheduled time. It is advised not to take a double dose to make up for a missed one.

Q: Can Sympal cause feeling anxious or dizzy?

A: Yes, official regulatory documents list dizziness and nervousness among the reported side effects. These are considered effects on the central nervous system (CNS).

Q: Do I need to change my diet while taking Sympal?

A: Official product information includes a warning that alcohol consumption is generally not recommended while taking this medicine. This is due to an increased risk of serious side effects, particularly gastrointestinal bleeding.

Q: Are there any common over-the-counter pain relievers that interact with Sympal?

A: Regulatory documents describe a contraindication or interaction warning regarding the concurrent use of Sympal with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). This is due to the increased risk of serious gastrointestinal side effects and bleeding.

Q: Can Sympal be used by people with a history of heart issues?

A: Official warnings indicate that Sympal should be used with caution in patients with a history of heart conditions, including hypertension (high blood pressure) or heart failure. Its use is typically contraindicated right before or after heart bypass surgery (CABG).

Q: What does the official drug label say about Sympal and pregnancy?

A: Sympal is not recommended during pregnancy unless the potential benefit justifies the potential risk to the fetus. Its use is generally contraindicated during the third trimester of pregnancy.

Q: Is Sympal available as a generic medicine?

A: Yes. Depending on the region and patent status, the active ingredient in Sympal (Dexketoprofen) is manufactured and distributed under its original brand name and by generic manufacturers.

Q: What is the difference between Sympal and a placebo in clinical trials?

A: In regulatory clinical trials, Sympal demonstrated an ability to provide pain relief compared to patients receiving an inactive substance (a placebo). This difference establishes the drug's efficacy (effectiveness) for its approved uses.

Q: Does Sympal have a risk of dependence or addiction?

A: Official regulatory information reports no habit-forming tendencies or risk of dependence associated with the use of Sympal. It is not classified as a controlled substance.

Q: Are there any specific supplements or vitamins to avoid while on Sympal?

A: Regulatory guidance indicates that patients should ensure all prescription and non-prescription medicines or supplements, especially those that affect blood clotting, are reviewed by a healthcare provider due to potential interactions.

Q: What should I do if I think I'm having a rare or serious side effect from Sympal?

A: Official guidance regarding rare or serious reactions is to discontinue use and seek immediate medical attention if signs of a serious reaction occur. Examples of such reactions listed in regulatory documents include severe rash, allergic swelling (angioedema), or gastrointestinal bleeding (such as black stools or vomiting blood).

Q: Can Sympal cause unusual changes in mood or behavior?

A: Regulatory documents note the possibility of central nervous system (CNS) effects, which have been reported to include changes such as nervousness, sleep disturbance, or mood changes.

Q: Is it possible to be allergic to the ingredients in Sympal?

A: Sympal is strictly contraindicated if a person has experienced a known hypersensitivity or allergy to the active ingredient (Dexketoprofen). It is also contraindicated if a person has experienced an allergic reaction or asthma symptoms after taking aspirin or any other Non-Steroidal Anti-Inflammatory Drug (NSAID).

Q: What are the most commonly reported side effects in the official documentation for Sympal?

A: The most commonly reported side effects in official documents are generally related to the gastrointestinal system. These may include nausea, vomiting, stomach pain, and diarrhea.

Q: Can people with diabetes use Sympal?

A: Regulatory documents do not list diabetes as a direct contraindication but advise that Sympal should be used with caution in patients with conditions that increase the risk of cardiovascular events. This may include patients with diabetes or high cholesterol.

Q: Is there a link between Sympal and weight gain or loss?

A: Official regulatory information mentions the possibility of fluid retention (edema) as a reported side effect, which can sometimes be noted as a change in body weight. Weight change itself is not a primary effect.

Q: Does Sympal interact with common cold or flu medications?

A: Regulatory documents include warnings concerning the concurrent use of Sympal with other NSAIDs, which are often found in common cold and flu medications. This is due to the increased risk of serious side effects, particularly those affecting the stomach and intestines.

Q: Are there any activities I should avoid while on Sympal (like driving)?

A: Official documentation warns that Sympal may cause side effects such as dizziness, drowsiness, or blurred vision. Because of these potential effects, regulatory information describes a need for caution when driving or operating heavy machinery.

Q: What is the official chemical name or ingredient of Sympal?

A: The active pharmaceutical ingredient in Sympal is Dexketoprofen (usually in the form of Dexketoprofen trometamol). This is the substance responsible for the medicine's effect.

Q: Does Sympal affect sleep patterns?

A: Disturbed sleep or drowsiness/sleepiness are among the central nervous system side effects that have been reported in official regulatory documents.

Q: Is it true that Sympal is only for temporary problems?

A: Yes, Sympal is officially approved and indicated for the short-term treatment of acute pain. Its regulatory approval is not intended for chronic (long-term) use.

Q: What is the official definition of the condition Sympal is meant to treat?

A: Sympal is indicated for acute pain that is classified as mild to moderate in intensity. This definition covers common short-term pain such as muscle/joint pain, dental discomfort, and menstrual cramps.

Q: Can Sympal be prescribed for more than one approved use?

A: Yes, Sympal is officially indicated for the short-term treatment of multiple types of acute mild to moderate pain, including musculoskeletal pain, dental pain, and menstrual pain (dysmenorrhoea).

Q: Are there any studies looking at the long-term safety of Sympal?

A: Regulatory bodies acknowledge that long-term safety data may be part of the missing information, especially since the medicine is indicated for short-term use. Safety is continuously monitored by regulatory agencies through pharmacovigilance (post-marketing surveillance).

Q: Does Sympal cause dry mouth or blurred vision?

A: Official documents list dry mouth and blurred vision among the adverse effects that have been reported by patients. If these occur, they are generally considered rare or uncommon.

Q: What types of medications are known to have major interactions with Sympal?

A: Regulatory documents highlight major interaction risks with medicines that affect blood clotting (such as anticoagulants), other NSAIDs, and certain medicines used to treat high blood pressure or kidney issues.

Q: Can people with certain allergies still take Sympal?

A: Sympal is strictly contraindicated if a person has experienced a known hypersensitivity or allergy to the active ingredient (Dexketoprofen). It is also contraindicated if a person has experienced an allergic reaction or asthma symptoms after taking aspirin or any other Non-Steroidal Anti-Inflammatory Drug (NSAID).

How should Sympal be stored and disposed of?

How to Store and Dispose of Sympal

The storage and disposal instructions for Sympal (Dexketoprofen trometamol) are based strictly on official regulatory labeling to ensure product stability and environmental safety.

Storage Requirement Rule as per Official Labeling
Temperature (Tablets) Do not store above 30 C.
Protection Keep in the outer carton to protect from light.
Child Safety Store out of the sight and reach of children.
Solution Handling The solution for injection/infusion, including the diluted form, must be protected from natural daylight.

Disposal of unused or expired product must be in accordance with local requirements. The medicine should not be disposed of via household wastewater or drains.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sympal found in:

A-Z Index: